NASDAQ:DYAIDyadic International Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dyadic International, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.88 +0.28 (+3.26 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$8.53Now: $8.88▼$9.0050-Day Range$8.24MA: $8.88▼$10.2652-Week Range$2.51Now: $8.88▼$10.98Volume97,149 shsAverage Volume129,958 shsMarket Capitalization$243.93 millionP/E RatioN/ADividend YieldN/ABeta0.49 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Dyadic International, Inc., a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corp. to express two therapeutic compounds using C1 production platform; and the Sanofi-Aventis Deutschland GmbH to express the potential of its C1 technology to produce various types of therapeutic compounds for manufacturing protein-based vaccine and biologic drugs; and research collaboration with global biotech company to explore the potential of its C1 technology to produce an active moiety. The company was founded in 1979 and is headquartered in Jupiter, Florida.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingDyadic International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, Dyadic International has a potential upside of 40.8% from its current price of $8.88.Amount of Analyst CoverageDyadic International has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesDyadic International has received 151 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDyadic International has received 173 “underperform” votes. (Add your “underperform” vote.)Community SentimentDyadic International has received 53.40% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Dyadic International and other stocks. Vote “Outperform” if you believe DYAI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DYAI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDyadic International does not currently pay a dividend.Dividend GrowthDyadic International does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyadic International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 24.80% of the stock of Dyadic International is held by insiders.Percentage Held by InstitutionsOnly 12.81% of the stock of Dyadic International is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dyadic International are expected to grow in the coming year, from ($0.23) to $0.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyadic International is -28.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyadic International is -28.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyadic International has a P/B Ratio of 6.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.29 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DYAI Previous Symbol CUSIPN/A CIKN/A Webwww.dyadic.com Phone561-743-8333Debt Debt-to-Equity RatioN/A Current Ratio28.89 Quick Ratio28.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.68 million Price / Sales145.20 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book6.73Profitability EPS (Most Recent Fiscal Year)($0.31) Net Income$-8,310,000.00 Net Margins-523.65% Return on Equity-22.87% Return on Assets-22.05%Miscellaneous Employees6 Outstanding Shares27,470,000Market Cap$243.93 million Next Earnings Date8/13/2020 (Confirmed) OptionableNot Optionable $8.88 +0.28 (+3.26 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive DYAI News and Ratings via Email Sign-up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter. Dyadic International (NASDAQ:DYAI) Frequently Asked Questions How has Dyadic International's stock been impacted by COVID-19 (Coronavirus)? Dyadic International's stock was trading at $4.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DYAI stock has increased by 88.1% and is now trading at $8.88. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Dyadic International? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dyadic International. When is Dyadic International's next earnings date? Dyadic International is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Dyadic International. How can I listen to Dyadic International's earnings call? Dyadic International will be holding an earnings conference call on Thursday, August 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Dyadic International's earnings last quarter? Dyadic International, Inc (NASDAQ:DYAI) announced its quarterly earnings data on Thursday, May, 14th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.06. The biotechnology company earned $0.32 million during the quarter, compared to the consensus estimate of $2.07 million. Dyadic International had a negative return on equity of 22.87% and a negative net margin of 523.65%. View Dyadic International's earnings history. What price target have analysts set for DYAI? 2 equities research analysts have issued 1 year price objectives for Dyadic International's stock. Their forecasts range from $11.00 to $14.00. On average, they anticipate Dyadic International's share price to reach $12.50 in the next year. This suggests a possible upside of 40.8% from the stock's current price. View analysts' price targets for Dyadic International. Has Dyadic International been receiving favorable news coverage? News headlines about DYAI stock have been trending negative on Monday, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dyadic International earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Dyadic International. Are investors shorting Dyadic International? Dyadic International saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 1,600,000 shares, a decline of 7.5% from the July 15th total of 1,730,000 shares. Based on an average trading volume of 279,000 shares, the days-to-cover ratio is currently 5.7 days. Currently, 8.3% of the shares of the stock are sold short. View Dyadic International's Short Interest. Who are some of Dyadic International's key competitors? Some companies that are related to Dyadic International include Replimune Group (REPL), Atara Biotherapeutics (ATRA), Poseida Therapeutics (PSTX), Passage Bio (PASG), Cellectis (CLLS), Vericel (VCEL), Autolus Therapeutics (AUTL), BioCryst Pharmaceuticals (BCRX), Krystal Biotech (KRYS), Osiris Therapeutics (OSIR), Oyster Point Pharma (OYST), Agenus (AGEN), Avrobio (AVRO), Aerie Pharmaceuticals (AERI) and Proteon Therapeutics (PRTO). View all competitors. What other stocks do shareholders of Dyadic International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dyadic International investors own include Endeavour Silver (EXK), Hecla Mining (HL), Silvercorp Metals (SVM), Endeavour Silver (EDR), Mandalay Resources (MND), Alibaba Group (BABA), Alphabet (GOOG), Pfizer (PFE), Gilead Sciences (GILD) and Exxon Mobil (XOM). Who are Dyadic International's key executives? Dyadic International's management team includes the following people: Mr. Mark A. Emalfarb, Founder, CEO, Pres & Director (Age 63)Ms. Ping Wang Rawson, Chief Accounting Officer & Principal Financial Officer (Age 43)Mr. Matthew S. Jones, Managing Director of Bus. Devel. & Licensing (Age 41)Dr. Ronen Tchelet, VP of Research & Bus. Devel. (Age 61)Ms. Ana Gómez Rodriguez, Sec. of the Board What is Dyadic International's stock symbol? Dyadic International trades on the NASDAQ under the ticker symbol "DYAI." Who are Dyadic International's major shareholders? Dyadic International's stock is owned by a variety of institutional and retail investors. Top institutional investors include New York State Common Retirement Fund (0.11%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.05%), SG Americas Securities LLC (0.04%), UBS Group AG (0.02%) and Strs Ohio (0.02%). Company insiders that own Dyadic International stock include Barry Buckland and Ronen Tchelet. View institutional ownership trends for Dyadic International. Which major investors are buying Dyadic International stock? DYAI stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Nelson Van Denburg & Campbell Wealth Management Group LLC, SG Americas Securities LLC, Strs Ohio, and UBS Group AG. View insider buying and selling activity for Dyadic International. How do I buy shares of Dyadic International? Shares of DYAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Dyadic International's stock price today? One share of DYAI stock can currently be purchased for approximately $8.88. How big of a company is Dyadic International? Dyadic International has a market capitalization of $243.93 million and generates $1.68 million in revenue each year. The biotechnology company earns $-8,310,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. Dyadic International employs 6 workers across the globe. What is Dyadic International's official website? The official website for Dyadic International is www.dyadic.com. How can I contact Dyadic International? Dyadic International's mailing address is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. The biotechnology company can be reached via phone at 561-743-8333 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
